Form 8-K - Current report:
SEC Accession No. 0001104659-22-011130
Filing Date
2022-02-03
Accepted
2022-02-03 06:39:53
Documents
16
Period of Report
2022-02-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm222755d1_8k.htm   iXBRL 8-K 34874
2 EXHIBIT 99.1 tm222755d1_ex99-1.htm EX-99.1 805274
3 EXHIBIT 99.2 tm222755d1_ex99-2.htm EX-99.2 811914
8 GRAPHIC tm222755d1_ex99-1img001.jpg GRAPHIC 4147
  Complete submission text file 0001104659-22-011130.txt   1971196

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20220203.xsd EX-101.SCH 4152
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20220203_def.xml EX-101.DEF 28239
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20220203_lab.xml EX-101.LAB 38353
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20220203_pre.xml EX-101.PRE 26849
10 EXTRACTED XBRL INSTANCE DOCUMENT tm222755d1_8k_htm.xml XML 7850
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 22586487
SIC: 2834 Pharmaceutical Preparations